These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 28243692)

  • 21. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.
    Rossi M; Carboni S; Di Berardino-Besson W; Riva E; Santiago-Raber ML; Belnoue E; Derouazi M
    Front Immunol; 2021; 12():695056. PubMed ID: 34276686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ectopic expression of cGAS in
    Waanders L; van der Donk LEH; Ates LS; Maaskant J; van Hamme JL; Eldering E; van Bruggen JAC; Rietveld JM; Bitter W; Geijtenbeek TBH; Kuijl CP
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
    Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
    J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation and Regulates Proinflammatory Responses Distinctly from STING Activation.
    Guo X; Shu C; Li H; Pei Y; Woo SL; Zheng J; Liu M; Xu H; Botchlett R; Guo T; Cai Y; Gao X; Zhou J; Chen L; Li Q; Xiao X; Xie L; Zhang KK; Ji JY; Huo Y; Meng F; Alpini G; Li P; Wu C
    Sci Rep; 2017 Jul; 7(1):6355. PubMed ID: 28743914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity.
    Mekers VE; Kho VM; Ansems M; Adema GJ
    Radiother Oncol; 2022 Sep; 174():158-167. PubMed ID: 35870728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity.
    Xie Y; Li K; Liang J; Wang K; Gong Z; Chen X
    Int J Pharm; 2024 Apr; 654():123955. PubMed ID: 38423155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour.
    Jeong SH; Yang MJ; Choi S; Kim J; Koh GY
    Nat Commun; 2021 Jul; 12(1):4405. PubMed ID: 34285232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
    Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways.
    Johnson BM; Uchimura T; Gallovic MD; Thamilarasan M; Chou WC; Gibson SA; Deng M; Tam JW; Batty CJ; Williams J; Matsushima GK; Bachelder EM; Ainslie KM; Markovic-Plese S; Ting JP
    J Immunol; 2021 May; 206(9):2015-2028. PubMed ID: 33820855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8
    Watkins-Schulz R; Tiet P; Gallovic MD; Junkins RD; Batty C; Bachelder EM; Ainslie KM; Ting JPY
    Biomaterials; 2019 Jun; 205():94-105. PubMed ID: 30909112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
    Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity.
    Schadt L; Sparano C; Schweiger NA; Silina K; Cecconi V; Lucchiari G; Yagita H; Guggisberg E; Saba S; Nascakova Z; Barchet W; van den Broek M
    Cell Rep; 2019 Oct; 29(5):1236-1248.e7. PubMed ID: 31665636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polysaccharide from
    Park HB; Hwang J; Zhang W; Go S; Kim J; Choi I; You S; Jin JO
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33302530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes.
    Kosaka A; Ishibashi K; Nagato T; Kitamura H; Fujiwara Y; Yasuda S; Nagata M; Harabuchi S; Hayashi R; Yajima Y; Ohara K; Kumai T; Aoki N; Komohara Y; Oikawa K; Harabuchi Y; Kitada M; Kobayashi H; Ohkuri T
    J Exp Med; 2021 Nov; 218(11):. PubMed ID: 34559187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
    Downey CM; Aghaei M; Schwendener RA; Jirik FR
    PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
    Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
    Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
    Corrales L; Glickman LH; McWhirter SM; Kanne DB; Sivick KE; Katibah GE; Woo SR; Lemmens E; Banda T; Leong JJ; Metchette K; Dubensky TW; Gajewski TF
    Cell Rep; 2015 May; 11(7):1018-30. PubMed ID: 25959818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.